open access

Vol 15, No 4 (2019)
Case report
Published online: 2019-08-21
Get Citation

Angiosarcoma — a malignant neoplasm secondary to radiotherapy for breast cancer in a female patient following breast-conserving treatment — a case report

Kamila Patrycja Kidrycka, Justyna Burzyńska-Śliwowska, Rafał Maksim, Andrzej Namiot, Marek Z. Wojtukiewicz, Ewa Sierko
DOI: 10.5603/OCP.2019.0012
·
Oncol Clin Pract 2019;15(4):217-222.

open access

Vol 15, No 4 (2019)
CASE REPORT
Published online: 2019-08-21

Abstract

Angiosarcoma is a rare malignant neoplasm, accounting for 1–2% of all sarcomas. The main cause of developing secondary angiosarcoma is radiotherapy. We analysed the case of a 52-year-old woman with breast cancer, who had undergone breast-conserving therapy. Four years after finishing treatment, she was diagnosed with secondary angiosarcoma in the irradiated area. The patient underwent a mastectomy. The disease relapsed six months after the operation in form of local recurrence, as well as liver and lung metastases. The patient’s condition gradually deteriorated despite treatment (chemotherapy and symptomatic management). The patient died due to cardiorespiratory failure nine months after the diagnosis of secondary malignancy.

Abstract

Angiosarcoma is a rare malignant neoplasm, accounting for 1–2% of all sarcomas. The main cause of developing secondary angiosarcoma is radiotherapy. We analysed the case of a 52-year-old woman with breast cancer, who had undergone breast-conserving therapy. Four years after finishing treatment, she was diagnosed with secondary angiosarcoma in the irradiated area. The patient underwent a mastectomy. The disease relapsed six months after the operation in form of local recurrence, as well as liver and lung metastases. The patient’s condition gradually deteriorated despite treatment (chemotherapy and symptomatic management). The patient died due to cardiorespiratory failure nine months after the diagnosis of secondary malignancy.

Get Citation

Keywords

angiosarcoma; breast cancer; chemotherapy; secondary malignant neoplasm; radiotherapy

About this article
Title

Angiosarcoma — a malignant neoplasm secondary to radiotherapy for breast cancer in a female patient following breast-conserving treatment — a case report

Journal

Oncology in Clinical Practice

Issue

Vol 15, No 4 (2019)

Article type

Case report

Pages

217-222

Published online

2019-08-21

DOI

10.5603/OCP.2019.0012

Bibliographic record

Oncol Clin Pract 2019;15(4):217-222.

Keywords

angiosarcoma
breast cancer
chemotherapy
secondary malignant neoplasm
radiotherapy

Authors

Kamila Patrycja Kidrycka
Justyna Burzyńska-Śliwowska
Rafał Maksim
Andrzej Namiot
Marek Z. Wojtukiewicz
Ewa Sierko

References (55)
  1. Ducimetière F, Lurkin A, Ranchère-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011; 6(8): e20294.
  2. Jodkiewicz Z, Kozakiewicz B, Roszkowska-Purska K, et al. Angiosarcoma w obszarze napromienianym po 16 latach obserwacji u chorej na raka piersi leczonej oszczędzająco — analiza przypadku. Nowotwory Journal of Oncology. 2014; 64(5): 396–400.
  3. Buehler D, Rice SR, Moody JS, et al. Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience. Am J Clin Oncol. 2014; 37(5): 473–479.
  4. Young RJ, Woll PJ, Staton CA, et al. Angiosarcoma. Lancet Oncol. 2010; 11(10): 983–991.
  5. Arora TK, Terracina KP, Soong J, et al. Primary and secondary angiosarcoma of the breast. Gland Surg. 2014; 3(1): 28–34.
  6. Sheppard DG, Libshitz HI. Post-radiation sarcomas: a review of the clinical and imaging features in 63 cases. Clin Radiol. 2001; 56(1): 22–29.
  7. Yap J, Chuba PJ, Thomas R, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2002; 52(5): 1231–1237.
  8. Thijssens KMJ, van Ginkel RJ, Suurmeijer AJH, et al. Radiation-induced sarcoma: a challenge for the surgeon. Ann Surg Oncol. 2005; 12(3): 237–245.
  9. Mery CM, George S, Bertagnolli MM, et al. Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival. Cancer. 2009; 115(18): 4055–4063.
  10. Buehler D, Rice SR, Moody JS, et al. Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience. Am J Clin Oncol. 2014; 37(5): 473–479.
  11. Fodor J, Orosz Z, Szabó E, et al. Angiosarcoma after conservation treatment for breast carcinoma: our experience and a review of the literature. J Am Acad Dermatol. 2006; 54(3): 499–504.
  12. Billings SD, McKenney JK, Folpe AL, et al. Cutaneous angiosarcoma following breast-conserving surgery and radiation: an analysis of 27 cases. Am J Surg Pathol. 2004; 28(6): 781–788.
  13. Penel N, Grosjean J, Robin YM, et al. Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases. Sarcoma. 2008; 2008: 459386.
  14. Berebichez-Fridman R, Deutsch YE, Joyal TM, et al. Stewart-Treves Syndrome: A Case Report and Review of the Literature. Case Rep Oncol. 2016; 9(1): 205–211.
  15. Hui A, Henderson M, Speakman D, et al. Angiosarcoma of the breast: a difficult surgical challenge. Breast. 2012; 21(4): 584–589.
  16. Torres KE, Ravi V, Kin K, et al. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol. 2013; 20(4): 1267–1274.
  17. Penel N, Marréaud S, Robin YM, et al. Angiosarcoma: state of the art and perspectives. Crit Rev Oncol Hematol. 2011; 80(2): 257–263.
  18. Forman D, Bennett B, Stafford J, et al. Exposure to vinyl chloride and angiosarcoma of the liver: a report of the register of cases. Br J Ind Med. 1985; 42(11): 750–753.
  19. Fury MG, Antonescu CR, Van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005; 11(3): 241–247.
  20. Kirova YM, Gambotti L, De Rycke Y, et al. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. Cancer. 2005; 104(4): 856–863.
  21. Huang J, Mackillop WJ. Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer. 2001; 92(1): 172–180.
  22. Virtanen A, Pukkala E, Auvinen A. Angiosarcoma after radiotherapy: a cohort study of 332,163 Finnish cancer patients. Br J Cancer. 2007; 97(1): 115–117.
  23. Seinen JM, Styring E, Verstappen V, et al. Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection. Ann Surg Oncol. 2012; 19(8): 2700–2706.
  24. Jallali N, James S, Searle A, et al. Surgical management of radiation-induced angiosarcoma after breast conservation therapy. Am J Surg. 2012; 203(2): 156–161.
  25. Li GZ, Fairweather M, Wang J, et al. Cutaneous radiation-associated breast angiosarcoma: radicality of surgery impacts survival. Ann Surg. 2017; 265(4): 814–820.
  26. Morgan EA, Kozono DE, Wang Q, et al. Cutaneous radiation-associated angiosarcoma of the breast: poor prognosis in a rare secondary malignancy. Ann Surg Oncol. 2012; 19(12): 3801–3808.
  27. Bentzen SM, Agrawal RK, Aird EGA, et al. START Trialists' Group, START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008; 371(9618): 1098–1107.
  28. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control andn survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 2881-10882 trial. J Clin Oncol. 2007; 25: 3259–3265.
  29. Vicini FA, Winter K, Wong J, et al. Initial efficacy results of RTOG 0319: Three dimensional conformal radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/II breast carcinoma. Int J Radiat Oncol Biol Phys. 2008; 72(1): S3.
  30. Yang WT, Hennessy BTJ, Dryden MJ, et al. Mammary angiosarcomas: imaging findings in 24 patients. Radiology. 2007; 242(3): 725–734.
  31. O'Neill AC, D'Arcy C, McDermott E, et al. Magnetic resonance imaging appearances in primary and secondary angiosarcoma of the breast. J Med Imaging Radiat Oncol. 2014; 58(2): 208–212.
  32. Hart J, Mandavilli S. Epithelioid angiosarcoma: a brief diagnostic review and differential diagnosis. Arch Pathol Lab Med. 2011; 135(2): 268–272.
  33. Li N, Cusidó MT, Navarro B, et al. Breast sarcoma. A case report and review of literature. Int J Surg Case Rep. 2016; 24: 203–205.
  34. Morgan MB, Swann M, Somach S, et al. Cutaneous angiosarcoma: a case series with prognostic correlation. J Am Acad Dermatol. 2004; 50(6): 867–874.
  35. Maddox JC, Evans HL. Angiosarcoma of skin and soft tissue: a study of forty-four cases. Cancer. 1981; 48(8): 1907–1921.
  36. Nicolas MM, Nayar R, Yeldandi A, et al. Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report. Acta Cytol. 2006; 50(6): 672–676.
  37. Tateishi U, Yamaguchi U, Seki K, et al. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology. 2007; 245(3): 839–847.
  38. Allison KH, Yoder BJ, Bronner MP, et al. Angiosarcoma involving the gastrointestinal tract: a series of primary and metastatic cases. Am J Surg Pathol. 2004; 28(3): 298–307.
  39. Bar R, Netzer A, Ostrovsky D, et al. Abrupt tonsillar hemorrhage from a metastatic hemangiosarcoma of the breast: case report and literature review. Ear Nose Throat J. 2011; 90(3): 116–120.
  40. Baum JK, Levine AJ, Ingold JA. Angiosarcoma of the breast with report of unusual site of first metastasis. J Surg Oncol. 1990; 43(2): 125–130.
  41. Lindford A, Böhling T, Vaalavirta L, et al. Surgical management of radiation-associated cutaneous breast angiosarcoma. J Plast Reconstr Aesthet Surg. 2011; 64(8): 1036–1042.
  42. Al-Benna S, Poggemann K, Steinau HU, et al. Diagnosis and management of primary breast sarcoma. Breast Cancer Res Treat. 2010; 122(3): 619–626.
  43. Feigenberg SJ, Mendenhall NP, Reith JD, et al. Angiosarcoma after breast-conserving therapy: experience with hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2002; 52(3): 620–626.
  44. Palta M, Morris CG, Grobmyer SR, et al. Angiosarcoma after breast-conserving therapy: long-term outcomes with hyperfractionated radiotherapy. Cancer. 2010; 116(8): 1872–1878.
  45. Mark RJ, Poen JC, Tran LM, et al. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer. 1996; 77(11): 2400–2406.
  46. Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007; 18(12): 2030–2036.
  47. Abraham JA, Hornicek FJ, Kaufman AM, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol. 2007; 14(6): 1953–1967.
  48. Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998; 21(3): 317–321.
  49. Issels RD, Lindner LH, Verweij J, et al. European Organization for the Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group and the European Society for Hyperthermic Oncology. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: the EORTC 62961-ESHO 95 randomized clinical trial. JAMA Oncol. 2018; 4(4): 483–492.
  50. Forscher C, Mita M, Figlin R. Targeted therapy for sarcomas. Biologics. 2014; 8: 91–105.
  51. Young RJ, Woll PJ. Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update. Memo. 2017; 10(4): 190–193.
  52. Ray-Coquard IL, Domont J, Tresch-Bruneel E, et al. Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. J Clin Oncol. 2015; 33(25): 2797–2802.
  53. D'Adamo DR, Dickson MA, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009; 27(19): 3133–3140.
  54. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009; 27(19): 3126–3132.
  55. Jagiełło-Wieczorek E, Świtaj T, Jagielska B, et al. Pazopanib as new therapeutic option in therapy of advanced soft tissue sarcoma. Onkol. Prak. Klin. 2014; 10: 24–31.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl